Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study

Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study

Background: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a Lactococcus cremoris strain that produces fibroblast growth factor-2, interleukin-4, and...

Full description

Saved in:
Bibliographic Details
Main Authors: Christoph Schindler, Jacek Mikosiński, Pawel Mikosiński, Hanna-Riikka Kärkkäinen, Mirka Sanio, Jere Kurkipuro, Igor Mierau, Wesley Smith, Aki Vartiainen, Laurent Décory, Dirk Weber, Thomas Wirth, Juha Yrjänheikki, Sebastian Schellong, Haritha Samaranayake
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Endocrinology and Metabolism
Online Access:https://doi.org/10.1177/20420188241294134
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/20420188241294134

Similar Items